Changes in haemostatic and platelet activation markers in non-dipper hypertensive patients

International Urology and Nephrology

Volumn 44, Issue 2, 2012, Pages 523-533

  Agorasti, Athanasia ^a   Mourvati, Efthimia ^b   Trivellas, Theodoros ^c   Papadopoulos, Vasilios ^b   Bazntiara, Ioanna ^b   Christoforidou, Anna ^b   Passadakis, Ploumis ^b  

^a General Hospital of Xanthi   (Greece)

^b UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^c TECHNOLOGICAL EDUCATIONAL INSTITUTE OF KAVALA   (Greece)

Author keywords

Ambulatory blood pressure monitoring; Coagulation activation; Dipping pattern; Fibrinolysis; Haemostatic markers; Hypertension; Non dipper; Platelet activation

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CALCIUM ANTAGONIST; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; PROTEIN C; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; HEMOSTASIS; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF VARIANCE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; BLOOD PRESSURE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOSTASIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PLATELET ACTIVATION; PLATELET COUNT;

EID: 84863090213     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-9926-9     Document Type: Article

References (57)

1. O'Brien E, Sheridan J, O'Malley K (1988) Dippers, nondippers. Lancet 2:397
2. Farmer CKT, Goldsmith DJA, Cox J, Dallyn P, Kingwood JC, Sharpstone P (1997) An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant 12:2301-2307 (Pubitemid 27474611)
3. Staessen J, Bieniaszewski L, O'Brien E, Gosse P, Hayashi H, Imai Y, Kawasaki T, Otsuka K, Palatini P, Thijs L, Fagard R (1997) Nocturnal blood pressure fall on ambulatory monitoring in a large international database. Hypertension 29:30-39 (Pubitemid 27078337)
4. Routledge F, McFetridge-Durdle J (2007) Nondipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 6:9-26 (Pubitemid 46282565)
5. Kanbay M, Turgut F, Uyar ME, Akcay A, Covic A (2008) Causes and mechanisms of nondipping hypertension. Clin Exp Hypertens 30:585-597
6. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G (1994) Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24:793-801
7. Routledge F, McFetridge-Durdle J, Dean CR (2007) Nighttime blood pressure patterns and target organ damage: a review. Can J Cardiol 23:132-138 (Pubitemid 46655428)
8. Mancia G, De Backer G, Dominiczak A et al (2007) Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187 (Pubitemid 46924065)
9. Redon J, Lurbe E (2008) Nocturnal blood pressure versus nondipping pattern. What do they mean? Hypertension 51:41-42 (Pubitemid 350307100)
10. Turfaner N, Karter Y, Curgunlu A, Ayan F, Mibmanli I, Sipabioglu F (2009) Blunted nocturnal fall in blood pressure in isolated clinical hypertension. Swiss Med Wkly 139:251-255
11. Staessen J, Thijs L, Fagard R, O'Brien E, Clement D, de Leeuw P, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 282:539-546 (Pubitemid 29380290)
12. Ohcubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y (2002) Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 20:2183-2189 (Pubitemid 35388236)
13. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E (2005) Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. The Dublin outcome study. Hypertension 46:156-161 (Pubitemid 40946507)
14. Fagard R, Celis H, Thijs L, Staessen J, Clement D, de Buyzere M, de Bacquer D (2008) Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51:55-61 (Pubitemid 350307104)
15. de la Sierra A, Redon J, Banegas J, Segura J, Parati G, Gorostidi M, de la Cruz J, Sobrino J, Llisterri J, Alonso J, Vinyoles E, Pallarés V, Sarría A, Aranda P, Ruilope L (2009) Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 53:466-472
16. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61-68 (Pubitemid 24203663)
17. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infraction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98:2241-2247 (Pubitemid 28533841)
18. Minnema MC, Peters RJG, de Winter R, Lubbers YPT, Barzegar S, Bauer KA, Rosenberg RD, Hack CE, ten Cate H (2000) Activation of clotting factors XI and IX in patients with acute myocardial infraction. Arterioscler Thromb Vasc Biol 20:2489-2493
19. Danesh J, Whincup P, Walker M, Thomson A, Rumley A (2001) Fibrin D-Dimer and coronary heart disease. Prospective study and meta-analysis. Circulation 103:2323-2327
20. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP, Factor VIII (1999) von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 105:110-116 (Pubitemid 29197151)
21. Yarnell JWG, Sweetnam PM, Rumley A, Lowe GDO (2000) Lifestyle and hemostatic risk factors for ischemic heart disease. The Caerphilly Study. Arterioscler Thromb Vasc Biol 20:271-279 (Pubitemid 30048375)
22. Lowe GDO, Rumley A, Sweetnam PM, Yarnell JWG (2001) Fibrin D-dimer, markers of goagulation activation and the risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost 85:822-827 (Pubitemid 32834192)
23. Lowe GDO, Sweetnam PM, Yarnell JWG, Rumley A, Rumley C, Bainton D, Ben-Shlomo Y (2004) C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease. The Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 24:1957-1962
24. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe GDO (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112:3080-3087 (Pubitemid 43113439)
25. Yarnell J, McCrun E, Rumley A, Patterson C, Salomaa V, Lowe GDO, Evans A (2005) Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study. Eur Heart J 26:332-342 (Pubitemid 40283092)
26. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L (2006) Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease. The AtheroGene Study. Arterioscler Thromb Vasc Biol 26:2793- 2799
27. Ardissino D, Merlini PA, Bauer KA, Galvani M, Ottani F, Franchi F, Bertocchi F, Ronsenberg RD, Mannucci PM (2003) Coagulation activation and long-term outcome in acute coronary syndromes. Blood 102:2731-2735 (Pubitemid 37248840)
28. Folsom AR, Wu KK, Shahar E, Davis CE (1993) Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 13:1829-1836 (Pubitemid 23360570)
29. Folsom AR, Wu KK, Rosamond WD, Sharrett R, Chambless LE (1997) Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:1102-1108
30. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto J, Rasmussen ML, Wu KK (1999) Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 100:736-742 (Pubitemid 29383644)
31. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK (2001) Prospective study of fibrinolytic factors and incident coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Artrerioscler Thromb Vasc Biol 21:611-617
32. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH, Sorlie P, Diao G, Sharrett R (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. The Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 166:1368-1373 (Pubitemid 44036348)
33. O'Brien E, Coats A, Owens P, Petrie J, Padfield PL, Littler WA, de Swiet M, Mee F (2000) Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society. BMJ 320:1128-1134 (Pubitemid 30213975)
34. von Känel R, Jain S, Mills PJ, Nelesen RA, Adler KA, Hong S, Perez CJ, Dimsdale JE (2004) Relation of nocturnal blood pressure dipping to cellular adhesion, inflammation and hemostasis. J Hypertens 22:2087-2093 (Pubitemid 39463800)
35. Henskens LH, Kroon AA, van Oostenbrugge RJ, Haest RJ, Lodder J, de Leeuw PW (2008) Different classifications of nocturnal blood pressure dipping affect the prevalence of dippers and nondippers and the relation with target-organ damage. J Hypertens 26:691-698 (Pubitemid 351354916)
36. Peirdomenico SD, Lapenne D, Gugliemi MD, Constantini F, Romano F, Schiavone C, Cuccurullo F, Mezzetti A (1997) Arterial disease in dipper and nondipper hypertensive patiens. Am J Hypertens 10:511-518 (Pubitemid 27239850)
37. Cuspidi C, Macca G, Sampieri L, Fusi V, Severgini B, Michev I, Salerno M, Margini F, Zanchetti A (2001) Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens 19:1539-1545 (Pubitemid 32783770)
38. Desideri G, Cipollone F, Valeri L, Grassi D, Necozione S, Croce G, Passacquale G, Garofalo A, Lippi C, Mezzetti A, Ferri C (2007) Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease. Am J Hypertens 20:70-76 (Pubitemid 46014062)
39. Alioglou E, Turk UO, Bicak F, Tengiz I, Atila D, Barisik V, Ercan E, Akin M (2008) Vascular endothelial functions, carotid intima-media thickness, and soluble CD40 ligand levels in dipper and nondipper essential hypertensive patients. Clin Res Cardiol 97:457-462
40. Cuspidi C, Michev I, Meani S, Valerio C, Betrazzoli G, Margini F, Zanchetti A, Non-dipper treated hypretensive patients do not have increased cardiac structural alterations. Cardiovasc Ultrasound. doi: 10.1186/1476-7120-1- 1
41. Lee KW, Blann AD, Lip GYH (2005) High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens 18: 104-115 (Pubitemid 40187356)
42. Soylu A, Yazici M, Duzenli MA, Tokac M, Ozdemir K, Gok H (2009) Relation between abnormalities in circadian blood pressure rhythm and target organ damage in normotensives. Circ J 73:899-904
43. Cuspidi C, Meani S, Salerno M, Valerio C, Fusi V, Severgini B, Lonati L, Margini F, Zanchetti A (2004) Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure. J Hypertension 22:273-280 (Pubitemid 38250985)
44. Parati G, Staessen JA (2007) Day-night blood pressure variations: mechanisms, reproducibility and clinical relevance. J Hypertens 25:2377-2380 (Pubitemid 350060375)
45. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund- Bodegärd K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Iamai Y, Wang J, Sandoya E, O'Brien E, Staessen JA (2007) Prognostic accuracy of day versus night ambulatory blood pressure: o cohort study. Lancet 370:1219-1229 (Pubitemid 47503300)
46. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P (1999) The relation of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19:1776-1783 (Pubitemid 29323839)
47. Bank I, Libourel EJ, Middeldorp S, Hamulya'k K, van Pampus ECM, Koopman MMW, Prins MH, van der Meer J, Büller HR (2005) Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3:79-84 (Pubitemid 41647118)
48. Lijfering WM, Veeger NJGM, Brouwer JLP, van der Meer J (2007) The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels. Haematologica 92:1703-1706 (Pubitemid 350248253)
49. Lowe GDO (2001) Factor IX and thrombosis. Br J Haematol 115:507-513 (Pubitemid 34015639)
50. Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Esnouf MP (2008) Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost 6:259-267
51. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 279:1477-1482 (Pubitemid 28228207)
52. Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. JAMA 294:1799-1809
53. Aono Y, Ohkubo T, Kikuya M, Hara A (2007) Kondo t, Obara T, Metoki H, Inoue R, Asayama K, Shintani Y, Hashimoto J, Totsune K, Hoshi H, Satoh H, Izumi SI, Imai Y, Plasma fibrinogen, ambulatory blood pressure, and silent cerebrovascular lesions. The Ohasama Study. Arterioscler Thromb Vasc Biol 27:963-968 (Pubitemid 46606732)
54. Rugman FP, Jenkins JA, Duguid JK, Maggs PB, Hay CR (1994) Prothrombin fragment F1 ? 2: correlations with cardiovascular risk factors. Blood Coagul Fibrinolysis 5:335-340 (Pubitemid 24173448)
55. Mercuri F, Giacomello R, Puglisi F, Colaone R, Fabbro D, Menegon MG, Ceriello A, Gonano F, Damante G, Factor V (2000) Leiden increases plasma F1 + 2 levels both in normal and deep venous thrombosis subjects. Haematologica 85:386-389 (Pubitemid 30318512)
56. Gouin-Thibault I, Arkam R, Nassiri S, de la Tourette A, Conard J, Horellou MH, Elalamy I, Samama MM (2002) Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thromb Res 107:7-11 (Pubitemid 35284419)
57. Cushman M, Lemaitr RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, Tracy RP (1999) Fibrinolytic activation markers predict myocardial infraction in the elderly. The Cardiovascular Health Study. Atheroscler Thromb Vasc Biol 19:493-498 (Pubitemid 29135146)